Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.

Vallejo-Vaz AJ, Bray S, Villa G, Brandts J, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I, Kees Hovingh G, Jozwiak JJ, Jukema JW, Gabor Kiss R, Kownator S, Iversen HK, Maher V, Masana L, Parkhomenko A, Peeters A, Clifford P, Raslova K, Siostrzonek P, Romeo S, Tousoulis D, Vlachopoulos C, Vrablik M, Catapano AL, Poulter NR, Ray KK, DA VINCI Study Investigators

Open source

DOI: 10.1007/s10557-022-07343-x
Published: 2023 Oct
Container: Cardiovascular drugs and therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10557-022-07343-x,
  title = {Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.},
  author = {Vallejo-Vaz AJ and Bray S and Villa G and Brandts J and Kiru G and Murphy J and Banach M and De Servi S and Gaita D and Gouni-Berthold I and Kees Hovingh G and Jozwiak JJ and Jukema JW and Gabor Kiss R and Kownator S and Iversen HK and Maher V and Masana L and Parkhomenko A and Peeters A and Clifford P and Raslova K and Siostrzonek P and Romeo S and Tousoulis D and Vlachopoulos C and Vrablik M and Catapano AL and Poulter NR and Ray KK and DA VINCI Study Investigators},
  year = {2023},
  journal = {Cardiovascular drugs and therapy},
  doi = {10.1007/s10557-022-07343-x},
  url = {https://doi.org/10.1007/s10557-022-07343-x}
}

RIS

TY  - JOUR
TI  - Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
AU  - Vallejo-Vaz AJ
AU  - Bray S
AU  - Villa G
AU  - Brandts J
AU  - Kiru G
AU  - Murphy J
AU  - Banach M
AU  - De Servi S
AU  - Gaita D
AU  - Gouni-Berthold I
AU  - Kees Hovingh G
AU  - Jozwiak JJ
AU  - Jukema JW
AU  - Gabor Kiss R
AU  - Kownator S
AU  - Iversen HK
AU  - Maher V
AU  - Masana L
AU  - Parkhomenko A
AU  - Peeters A
AU  - Clifford P
AU  - Raslova K
AU  - Siostrzonek P
AU  - Romeo S
AU  - Tousoulis D
AU  - Vlachopoulos C
AU  - Vrablik M
AU  - Catapano AL
AU  - Poulter NR
AU  - Ray KK
AU  - DA VINCI Study Investigators
PY  - 2023
JO  - Cardiovascular drugs and therapy
DO  - 10.1007/s10557-022-07343-x
UR  - https://doi.org/10.1007/s10557-022-07343-x
ER  -

APA

AJ, V., S, B., G, V., J, B., G, K., J, M., M, B., S, D. S., D, G., I, G., G, K. H., JJ, J., JW, J., R, G. K., S, K., HK, I., V, M., L, M., A, P., A, P., P, C., K, R., P, S., S, R., D, T., C, V., M, V., AL, C., NR, P., KK, R., & Investigators, D. V. S. (2023). Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.. Cardiovascular drugs and therapy. https://doi.org/10.1007/s10557-022-07343-x

Source records

pubmed · retrieved 2026-09-25T21:01:16.356Z
europe-pmc · retrieved 2026-09-25T21:01:16.361Z